New antibody fragments light up tumors in early imaging trial
NCT ID NCT06645808
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the body, how safe they are, and whether they can help spot tumors more clearly. About 32 adults with various solid tumors will take part.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- 89Zr-DFO-N-Suc-F8scFv and 89Zr-DFO-N-Suc-C9scFv (radiolabeled antibody fragments)
- What this could lead to
- If successful, this could pave the way for better imaging and targeted treatments for many solid tumor types.
- What could go wrong
- This is a very early phase 0 trial with only 32 participants, so results may not apply broadly. The main goal is imaging, not treatment, so direct patient benefit is unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Center Groningen (UMCG)
RECRUITINGGroningen, Provincie Groningen, 9713GZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may spare cancer patients unneeded iron infusions
- Peppermint and lemon scents put to the test against chemo nausea
- Can tape or a pressure vest ease Post-Radiation breast swelling?
- Can a new pill keep HER2-Positive breast cancer from coming back?
- Can a new PET tracer outsmart head and neck cancer metastases?
- Personalized chemo: could tumor DNA hold the key to better breast cancer treatment?